AnaptysBio, Inc. Common Stock When Issued
ANABV
NASDAQ Global Select43.80
USD
+0.80
- -
ISIN
US0327242055
CUSIP
032724205
Return %
Stock
S&P500
1Y
-3.78
19.01
3Y
-3.78
65.48
5Y
-3.78
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel R. Faga
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- San Diego United States of America
- IPO Date
- Apr 6, 2026
- Website
- anaptysbio.com
- Similar Companies
- Business
- AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of antibody therapeutics for autoimmune and inflammatory diseases, headquartered in San Diego, California, and founded in 2005. The company advances a diversified pipeline of immune-modulating antibodies and related biologics across multiple stages of development, with strategic collaborations and ongoing clinical initiatives. Main products and services - Antibody discovery and generation platforms: proprietary technologies for rapid generation and optimization of therapeutic antibodies. - Therapeutic antibody programs in immunology: rosnilimab (PD-1 agonist) advancing in Phase 2 trials for rheumatoid arthritis; ANB032 (BTLA agonist) in Phase 2b for atopic dermatitis; ANB033 and ANB101 (preclinical immune cell modulators) slated for clinical development. - Clinical-stage programs: development, regulatory liaison, and trial execution for antibody therapeutics addressing autoimmune and inflammatory diseases. - Collaboration and licensing services: strategic partnerships with larger pharmaceutical companies that provide funding, joint development, and commercialization rights as part of research collaborations. Latest major company changes - Strategic updates and clinical milestones: ongoing enrollment in multiple Phase 2 trials for checkpoint agonist programs (ANB032, rosnilimab) with expected topline data timelines in 2024–2025 windows; expansion of the portfolio with preclinical programs advancing toward clinical development (ANB033, ANB101). - Partnerships and licensing arrangements: continued collaboration with major pharmaceutical partners to support development, manufacturing, and potential commercialization pathways for antibody therapies. - Corporate and organizational developments: sustained focus on streamlining operations to support rapid clinical development and expand manufacturing capabilities as pipeline activities scale; any reorganization or branding updates have aligned with its status as a clinical-stage company focusing on immunology therapeutics. Additional context - Industry and segments: biotechnology; immunology, autoimmune diseases, inflammatory conditions; therapeutic antibodies; platform technology development. - Target markets and customers: biopharmaceutical developers, healthcare providers, clinical researchers, and potential future commercial partners in global markets. - Geographic footprint: operations and development activities centered in the United States (headquarters in San Diego), with potential international trials and collaborations as the pipeline progresses. - Founding year and headquarters: 2005; headquarters in San Diego, California. - Subsidiaries and parent relationships: operates as an independent publicly traded company with ongoing collaborations and licensing arrangements, including notable industry partnerships. Note: This description reflects publicly available information on AnaptysBio’s core activities, pipeline, and recent strategic movements up to the latest disclosed updates. For precision on specific trial milestones, collaboration terms, or regulatory statuses, refer to the company’s investor relations communications and regulatory filings.